Msd

© GettyImages/Pheelings Media

FDA rebuff for Keytruda in breast cancer indication

By Jane Byrne

A couple of new developments to report in relation to Merck, known as MSD outside the US and Canada: the first being the rejection by the US FDA of the company’s application to use its anti-PD-1 therapy, Keytruda, in certain breast cancer patients.

(Image: Getty/wildpixel)

Delays at MSD’s CMO prompt Sinemet shortage

By Flora Southey

MSD has warned regulators to expect a shortage of its Parkinson’s medicine, Sinemet, due to production constraints at a contract manufacturer’s facility.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All